BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
2.330
+0.070 (3.10%)
At close: Oct 24, 2025, 4:00 PM EDT
2.360
+0.030 (1.29%)
Pre-market: Oct 27, 2025, 4:51 AM EDT
BioXcel Therapeutics Revenue
BioXcel Therapeutics had revenue of $120.00K in the quarter ending June 30, 2025, a decrease of -89.13%. This brings the company's revenue in the last twelve months to $868.00K, down -63.88% year-over-year. In the year 2024, BioXcel Therapeutics had annual revenue of $2.27M with 64.20% growth.
Revenue (ttm)
$868.00K
Revenue Growth
-63.88%
P/S Ratio
12.34
Revenue / Employee
$23,459
Employees
37
Market Cap
45.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.27M | 886.00K | 64.20% |
| Dec 31, 2023 | 1.38M | 1.01M | 268.00% |
| Dec 31, 2022 | 375.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
BTAI News
- 2 days ago - Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 12 days ago - BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes - GlobeNewsWire
- 13 days ago - BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation - GlobeNewsWire
- 5 weeks ago - BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements - GlobeNewsWire
- 6 weeks ago - BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript) - Seeking Alpha
- 6 weeks ago - BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients - Benzinga
- 6 weeks ago - BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 7 weeks ago - BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire